New study examines bleeding treatment in blood thinner patients
NCT ID NCT05898412
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 217 Dutch patients who were hospitalized with serious bleeding while taking a type of blood thinner called a factor Xa inhibitor. All patients received a drug called andexanet alfa to reverse the bleeding. Researchers wanted to learn more about the patients' characteristics and what happened after treatment, including any blood clots. The study is based on past medical records from about 10 hospitals in the Netherlands.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
andexanet alfa
What this could lead to
If successful, this study could help doctors better understand which patients might benefit most from andexanet alfa and how to use it safely.
What could go wrong
This is a small, retrospective study that only looks back at past data. It cannot prove cause and effect, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Amsterdam, Netherlands